The aim of the study – to determine the frequency of preeclampsia in pregnant females with anterior location of the placenta and to determine the prognostic significance when combined with a marker of acute renal damage – cystatin C level.

Materials and Methods. In 2018–2020, a prospective cohort study that enrolled 91 pregnant women at their second trimester of gestation was conducted at Maternity Clinic and Obstetric Hospital of Maternity Hospital No. 2, Odesa. The group with the anterior location of the placenta consisted of 47 (51.65 %) pregnant women and 44 (48.35 %) had the posterior location of the placenta. Assessment of serum cystatin C was performed in women without clinical manifestations of PE at the second or third trimester of gestation (18–36 weeks), the average term was (32.22±0.41) weeks of pregnancy (p=0.011).

Results and Discussion. 28.57 % of pregnant women were subsequently diagnosed with preeclampsia (PE), of whom 19 (20.88 %) had anterior and 7 (7.69 %) posterior placenta location. Body mass index (BMI) before pregnancy, age, and height: no statistically significant difference observed between groups (p>0.05). Analysis of maternal factors of PE in relation to the anterior location of the placenta: odds ratio (OR) higher than 1.0 was noted for combination with obesity (OR 2.38 (95 % CI 0.75–7.53)), the age over 35 years (OR 1.01 (95 % CI 0.41–2.49)) and history of PE during previous pregnancy (OR 1.38 (95 % CI 0.21–9.01)), but no statistical significance was observed (p>0.05). When analyzing cystatin C values over 1.0 mmol/l relative to the anterior location of the placenta, the OR was 3.92 (95 % CI 1.45–10.57), sensitivity 84.09 %, specificity 42.55 %, accuracy 62.64 % were reported, p=0.011. When analyzing the frequency of preeclampsia in the anterior location of the placenta, the OR was 3.59 (95 % CI 1.32 - 9.71), sensitivity 84.09 %, specificity 40.43 %, accuracy 61.54 % were reported with statistical significance p=0.019.

Conclusions. The risk of preeclampsia in patients with the anterior location of the placenta increases by 3.59 times with a prognostic accuracy of 61.54 %. To increase the prognostic significance for the detection of preeclampsia in women with anterior location of the placenta, it is recommended to assess the serum level of cystatin C.

Key words: preeclampsia; anterior location of the placenta; cystatin C; screening.

ANTERIOR PLACENTA POSITION AS A CAUSING FACTOR OF PRE-ECLAMPSIA

©L. I. Berlinska, V. G. Marichereda, O. M. Pavlovskaya, Y. Y. Petrovskiy
Odesa National Medical University

The risk of preeclampsia in patients with the anterior location of the placenta increases by 3.59 times with a prognostic accuracy of 61.54 %. To increase the prognostic significance for the detection of preeclampsia in women with anterior location of the placenta, it is recommended to assess the serum level of cystatin C.
INTRODUCTION. The International Unions of Obstetrics and Gynecology pay special attention to factors that cause the development of preeclampsia (PE) – one of the most important diseases of pregnant women, leading to maternal and perinatal morbidity and mortality. Modern complex PE screenings are based on case history, bio-markers and Dopplerography of uterine arteries [1]. The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) recommends the use of a pulsation index to study uterine artery resistance in the context of PE screening [2]. Use of multi-parameter complex models that include Doppler imaging of the uterine arteries, enables 90 % accuracy of early PE detection [3]. According to the algorithm of the Fetal Medicine Foundation (FMF), which combines maternal factors, mean blood pressure, pulsation index of uterine arteries and placental growth factor, the probability of developing PE before 37 gestation weeks is as high as 75 % [4]. It is assumed that the development of maternal PE syndrome during second and third trimesters is facilitated by abnormal placentaation at the beginning of the first trimester [5]. As a result, it leads to histological and morphological changes in the pre-eclampsia placenta (placental and vascular villi lesions, myocardial infarction and calcification, retro-placental hematoma, umbilical cord marginal position) [6]. Considering the anatomical features of the uterine blood supply and based on placental theory, it is possible to assume a relationship between the location of the placenta and preeclampsia. The location of the placenta within the uterus is determined by ultrasound from gestation week 15–16. The use of ultrasound as a tool for PE screening meets the basic requirements: availability, low cost, non-invasiveness and high specificity and sensitivity in complex models.

THE AIM OF THE STUDY – to determine the frequency of preeclampsia in pregnant females with anterior location of the placenta and to determine the prognostic significance when combined with a marker of acute renal damage – cystatin C level.

MATERIALS AND METHODS. In 2018–2020, a prospective cohort study of 91 pregnant women in the second trimester of gestation was evaluated in the clinic and obstetric hospital at Maternity Hospital No. 2, Odesa. The group with anterior position of placenta consisted of 47 (51.65 %) pregnant females; 44 (48.35 %) females had posterior position of placenta. PE was determined according to the recommendations of the International Society for the Study of Hypertension in Pregnancy: systolic blood pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg when measured at least 2 times every 4 hours in females who had normal blood pressure before pregnancy, with one or more of the following conditions detected after gestation week 20: proteinuria, acute renal failure, acute liver failure, neurological or hematological complications, uteroplacental dysfunction [7]. Thus, 28.57 % of pregnant women belong to the subgroup with PE and 71.43 % – women who had not developed PE. Thus, 28.57 % of pregnant women belong to the subgroup with PE and 71.43 % – women who had no developed PE.

Ultrasound assessment of the location of the placenta was performed at 18–20 weeks of gestation using a universal device of ultrasound examination “Toshiba Aplio 400” (Japan).

Studies of serum cystatin C level were conducted in females without clinical manifestations of PE during the second or third trimester of gestation (18–36 weeks), the average term was (32.2±0.41) weeks of pregnancy (p=0.011).

Statistical analysis.

The data obtained in the study were entered into the MS-Excel database and analyzed using the statistical program MedCalc for PC, version 12.7.0 (MedCalc Software, Belgium). Between group comparisons were performed by one of the methods of ANOVA. To identify the relationship of the most significant factors, the odds ratio (OR) is calculated, with values greater than 1.0, a direct relationship is observed. P value <0.05 was considered statistically significant.

RESULTS AND DISCUSSION. Preeclampsia was developed in 26 (28.57 %) pregnant females, 19 (20.88 %) of them had anterior position of placenta and 7 (7.69 %) had posterior placenta location.

Body mass index (BMI) before pregnancy, age, and height of women with anterior location of the placenta were not associated with statistically significant probability of PE development (p>0.05) (Table 1).

Odds ratio (OR) greater than 1.0 was noted for combination of PE with obesity (OR 2.38 (95 % CI 0.75–7.53), age over 35 years (OR 1.01 (95 % CI 0.41–2.49)) (Table 2) and history of PE during previous pregnancy (OR 1.38 (95 % CI 0.21–9.01)) (Table 3), but no statistical significance was observed (p>0.05).

It can be assumed that none of the maternal factors of PE, such as maternal PE, chronic hypertension, history of renal disease, first pregnancy, and the interval between pregnancies >10 years, is not related to the location of the placenta as a factor of preeclampsia development.

In our previous study of renal biomarkers cystatin C was identified as a predictor of PE development during the second and third trimesters. It has been demonstrated that cystatin
Table 1. Characteristics of age, height and BMI of pregnant women with preeclampsia or without preeclampsia depending on the location of the placenta

<table>
<thead>
<tr>
<th>Preeclampsia</th>
<th>Maternal age, years</th>
<th>Height, cm</th>
<th>BMI</th>
<th>Posterior</th>
<th>Anterior</th>
<th>Posterior</th>
<th>Anterior</th>
<th>Posterior</th>
<th>Anterior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without PE</td>
<td>30.89±0.99 (% 95 CI: 28.94–32.84 n=37)</td>
<td>29.93±1.06 (% 95 CI: 27.86–32 n=28)</td>
<td>168.38±0.81 (% 95 CI: 169.96 n=37)</td>
<td>166.71±2.1 (% 95 CI: 69.83 n=37)</td>
<td>24.35±0.85 (% 95 CI: 22.69–26.01 n=37)</td>
<td>24.43±1.12 (% 95 CI: 22.24–26.62 n=28)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With PE</td>
<td>29.29±1.48 (% 95 CI: 26.39–32.18 n=19)</td>
<td>31.16±1.62 (% 95 CI: 27.98–34.34 n=19)</td>
<td>166.2±6.7 (% 95 CI: 171.24 n=7)</td>
<td>162.37±1.4 (% 95 CI: 165.11 n=9)</td>
<td>25.71±2.74 (% 95 CI: 20.33–31.09 n=9)</td>
<td>27.25±1.48 (% 95 CI: 24.34–30.16 n=19)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Σ</td>
<td>30.64±0.87 (% 95 CI: 28.94–32.34 n=44)</td>
<td>30.43±0.9 (% 95 CI: 28.66–32.19 n=47)</td>
<td>169±0.8 (% 95 CI: 169.56 n=44)</td>
<td>164.36±1.38 (% 95 CI: 167.07 n=47)</td>
<td>24.56±0.82 (% 95 CI: 22.95–26.18 n=44)</td>
<td>25.57±0.91 (% 95 CI: 23.79–27.35 n=47)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p</td>
<td>0.505</td>
<td>0.51</td>
<td>0.281</td>
<td>0.239</td>
<td>0.552</td>
<td>0.129</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Characteristics of obesity and age of the pregnant woman ≥35 years depending on the location of the placenta

<table>
<thead>
<tr>
<th>Placenta location</th>
<th>Degree of obesity, %</th>
<th>Maternal age, years, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Absent</td>
<td>I</td>
</tr>
<tr>
<td>Anterior</td>
<td>39 (42.86 %)</td>
<td>1 (1.1 %)</td>
</tr>
<tr>
<td>Posterior</td>
<td>36 (39.56 %)</td>
<td>7 (6.9 %)</td>
</tr>
<tr>
<td>Σ</td>
<td>75 (82.2 %)</td>
<td>8 (8.79 %)</td>
</tr>
</tbody>
</table>

Table 3. Characteristics of maternal preeclampsia factors depending on the location of the placenta

<table>
<thead>
<tr>
<th>Maternal factors of PE development</th>
<th>Placenta location</th>
<th>Σ</th>
<th>Odds ratio, confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Posterior</td>
<td>Anterior</td>
<td></td>
</tr>
<tr>
<td>PE during previous pregnancy</td>
<td>2 (3.64 %)</td>
<td>3 (5.45 %)</td>
<td>5 (9.09 %)</td>
</tr>
<tr>
<td>PE in the mother</td>
<td>4 (4.4 %)</td>
<td>4 (4.4 %)</td>
<td>8 (8.79 %)</td>
</tr>
<tr>
<td>Chronic hypertension</td>
<td>1 (1.1 %)</td>
<td>2 (2.2 %)</td>
<td>3 (3.3 %)</td>
</tr>
<tr>
<td>History of renal disease</td>
<td>10 (10.99 %)</td>
<td>11 (12.09 %)</td>
<td>21 (23.08 %)</td>
</tr>
<tr>
<td>The first pregnancy</td>
<td>18 (19.78 %)</td>
<td>18 (19.78 %)</td>
<td>36 (39.56 %)</td>
</tr>
<tr>
<td>In vitro fertilization</td>
<td>3 (3.3 %)</td>
<td>2 (2.2 %)</td>
<td>5 (5.49 %)</td>
</tr>
<tr>
<td>APS</td>
<td>1 (1.1 %)</td>
<td>1 (1.1 %)</td>
<td>2 (2.2 %)</td>
</tr>
<tr>
<td>Interval between pregnancies&gt; 10 years</td>
<td>4 (4.4 %)</td>
<td>4 (4.4 %)</td>
<td>8 (8.79 %)</td>
</tr>
</tbody>
</table>

C value of 1.08 is associated with PE sensitivity 87.5 % and specificity level as high as 100 % [8]. When analyzing the ratio of cystatin C level over 1.0 mmol/l to the anterior location of the placenta, the OR was 3.92 (95 % CI 1.45–10.57), sensitivity 84.09 %, specificity 42.55 %, and accuracy 62.64 %, p=0.011 (Table 4). It is possible to assume that anterior location of the placenta, is associated with the 3.92 – fold higher probability of increased cystatin C level, which in turn will lead to the development of PE.

When analyzing creatinine level at the preclinical stage of PE, statistical difference between anterior (78.1±1.8 (95 % CI: 74.57–81.63)) and posterior (72.8±4.56 (95 % CI: 63.91–81.77)) position of placenta was not observed (p=0.203), but the significance was noted for posterior placentation between

ISSN 2411–4944. Актуальні питання педіатрії, акушерства та гінекології. 2020. № 2
Акушерство та гінекологія

Table 4. Characteristics of the relationship between cystatin C and preeclampsia depending on the location of the placenta

<table>
<thead>
<tr>
<th>Placenta location</th>
<th>Cystatin C, mg / l</th>
<th>Σ (p&lt;0.05)</th>
<th>Preeclampsia</th>
<th>Σ (p&lt;0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;1.0</td>
<td>&gt;1.0</td>
<td>Without PE</td>
<td>Without PE</td>
</tr>
<tr>
<td>Anterior</td>
<td>27 (29.67 %)</td>
<td>20 (21.98 %)</td>
<td>47 (51.65 %)</td>
<td>28 (30.77 %)</td>
</tr>
<tr>
<td>Posterior</td>
<td>37 (40.66 %)</td>
<td>7 (7.69 %)</td>
<td>44 (48.35 %)</td>
<td>37 (40.66 %)</td>
</tr>
<tr>
<td>Σ</td>
<td>64 (70.33 %)</td>
<td>27 (29.67 %)</td>
<td>91 (100 %)</td>
<td>65 (71.43 %)</td>
</tr>
</tbody>
</table>

Pearson criterion, χ²=6.51, p=0.011

women with and without PE (70.92±2.25 (95 % CI: 66.51–75.33)), p=0.026. Urea levels in the preeclamptic group are statistically significant between posterior (4.97±1.31 (95 % CI: 2.41–7.54) and anterior placentation groups (3.19±0.19 (95 % CI: 2.82–3.55) (p=0.041) However, creatinine and urea levels do not exceed the reference values; therefore, this parameter is not applicable for PE screening (Fig. 1).

When analyzing the frequency of preeclampsia in patients with anterior location of the placenta, the OR was 3.59 (95 % CI 1.32–9.71) with statistical significance p=0.011 (Table 4). When using the anterior location of the placenta as a screening marker of PE, sensitivity 84.09 %, specificity 40.43 %, frequency of positive predictions 56.92 % and negative predictions 73.08 %, accuracy 61.54 % were reported.

Preeclampsia is a multisystem syndrome that leads not only to maternal and perinatal complications and mortality during pregnancy and childbirth, but also has an impact on the development of diseases such as chronic renal and cardiovascular failure, hypertension and diabetes at a later date [9–11]. Thus, this leads to the need to investigate the screening markers of PE and pay special attention to the most available tests. The use of ultrasound during the second trimester of pregnancy is economically justified and routinely used in everyday practice.

The uterine arteries give branches that give supply for different parts of the uterus and play an important role in maintaining blood supply during uterine growth during pregnancy [12]. In the research of Kozlov S.V et al., asymmetry of blood supply of the right and left halves of the uterus and inequality of arterial inflow to the anterior and posterior walls of the uterus were revealed [13]. It is possible to assume that there is an incomplete trophoblastic invasion of a placenta that leads to complications of pregnancy, including PE. Some researchers have described the effects of lateral placenta on the development of disorders during pregnancy between patients with central and lateral placenta position [14]. This is consistent with other studies which suggest that maternal and neonatal complications are more likely to occur in association with lateral placental compared to the central location and associated PE with the right side placenta position [14]. The risk of hypertension development during pregnancy with lateral placenta position in the studies of Prathima A and Reddi Rani P. was: OR 3.5 (95 % CI 1.4–8.6) with a sensitivity 28.1 % and a specificity level 87.6 % [15].

In the analysis of Keshavarz E et al. lateral placenta position was associated with preeclampsia in 47.6 % (20 of 42) cases, while other locations were associated with preeclampsia in 30 % of patients (101 of 337) (p=0.02, OR 2.1, 95 % CI: 1.1–4.1). In the group of preeclampsia the right lateral placenta position was more often observed, and in the normal group the left lateral placenta position was common [16]. This is consistent with other studies which suggest that the lateral location of the placenta is associated with an increased risk of preeclampsia [17–19].

In contrast to these studies, Salama-Bello R. et al. did not report any difference in the incidence of hypertensive disorders during pregnancy between patients with central and lateral placenta position [20]. PE and severe hypertension were more common in patients with posterior placentalation; the analysis of Prathima A and others, involved only 11

**p<0.001**

***p<0.001**

*p<0.05**

Fig. 1. Serum Cystatin C (a), Creatinine (b) and Urea (c) in pregnant women with preeclampsia depending on the location of the placenta.
women with PE; therefore the results of this study are not statistically significant [15]. Jenabi E et al. in a meta-analysis of nine studies have demonstrated that the chances of preeclampsia were 0.55 (95% CI: 0.26–0.85) in cases of placenta previa compared to control groups and 0.17 (95% CI 0.07–0.27) in studies with variable adjustment. Thus, placenta previa has been shown to be associated with a reduction in the incidence of preeclampsia [21]. This may be due to the abundant blood supply, which in turn contributes to adequate trophoblast invasion.

Thus, research data on the relationship between placenta location and PE development are contradictory and require additional investigation.

In our study, attention was paid to the anterior and posterior location of the placenta, which was determined during the second ultrasound screening, and the prevalence of PE in these groups; use of this predictor as a part of complex screening has been considered.

In this study that enrolled 91 pregnant women, PE has developed in 26 (28.57 %) females, of whom 19 (20.88 %) had anterior placenta position, while 7 (7.69 %) had a posterior placental location. We found that the risk of PE is 3.59 times higher in patients with the anterior location compared to patients with the posterior location (p=0.019). Our findings are consistent with other authors who link the anterior placenta to PE with a statistical significance of p<0.001 [22, 23]. Anterior placenta locations is not related to other maternal factors, but is statistically significant in combination with the renal biomarker of acute renal damage, cystatin C level (p=0.011), for prediction of PE.

Rationale for the use of cystatin C level assessment in PE screening was demonstrated in our previous study, the value is statistically significant (p<0.001) and the value is over than 1.08 is a reliable marker of preeclampsia at the preclinical stage of implementation [24].

CONCLUSIONS. 1. The risk of preeclampsia is 3.59 folds higher in patients with the anterior location of placenta.
2. Determining the anterior location of the placenta during ultrasound screening during the second trimester of pregnancy can predict the development of preeclampsia with an accuracy level 61.54 %.
3. The use of ultrasound is an economical, non-invasive and available method of diagnosis.
4. To increase the prognostic significance for the detection of preeclampsia in women with anterior location of the placenta, it is recommended to assess the serum level of cystatin C.

LITERATURE
REFERENCES


Received 22.09.20
Accepted 23.10.20
Address for correspondence: ludaberlinskaja@gmail.com

Aкуше́рство та гінекологія —